The Brn-2 Transcription Factor Links Activated BRAF to Melanoma Proliferation

REFERENCES

• Angel, P., Imagawa M., Chiu R., Stein B., Imbra R. J., Rahmsdorf H. J., Jonat C., Herrlich P., and Karin M.. 1987. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 49:729–739.
   PubMed Web of Science ®Google Scholar
• Bennett, D. C., Cooper P. J., Dexter T. J., Devlin L. M., Heasman J., and Nester B.. 1989. Cloned mouse melanocyte lines carrying the germline mutations albino and brown: complementation in culture. Development 105:379–385.
   PubMedGoogle Scholar
• Bert, A. G., Burrows J., Hawwari A., Vadas M. A., and Cockerill P. N.. 2000. Reconstitution of T cell-specific transcription directed by composite NFAT/Oct elements. J. Immunol. 165:5646–5655.
   PubMed Web of Science ®Google Scholar
• Carreira, S., Dexter T. J., Yavuzer U., Easty D. J., and Goding C. R.. 1998. Brachyury-related transcription factor Tbx2 and repression of the melanocyte-specific TRP-1 promoter. Mol. Cell. Biol. 18:5099–5108.
   PubMed Web of Science ®Google Scholar
• Carreira, S., Liu B., and Goding C. R.. 2000. The gene encoding the T-box transcription factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes. J. Biol. Chem. 275:21920–21927.
   PubMed Web of Science ®Google Scholar
• Chin, L., Merlino G., and Depinho R. A.. 1998. Malignant melanoma: modern black plague and genetic black box. Genes Dev. 12:3467–3481.
   PubMedGoogle Scholar
• Chin, L., Pomerantz J., and DePinho R. A.. 1998. The INK4a/ARF tumor suppressor: one gene—two products—two pathways. Trends Biochem. Sci. 23:2822–2834.
   Google Scholar
• Chin, L., Pomerantz J., Polsky D., Jacobson M., Cohen C., Cordon C., C., Horner II J. W., and DePinho R. A.. 1997. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 11:2822–2834.
   PubMed Web of Science ®Google Scholar
• Cohen, Y., Goldenberg-Cohen N., Parrella P., Chowers I., Merbs S. L., Pe'er J., and Sidransky D.. 2003. Lack of BRAF mutation in primary uveal melanoma. Investig. Ophthalmol. Vis. Sci. 44:2876–2878.
   PubMed Web of Science ®Google Scholar
• Cruz, F., 3rd, Rubin B. P., Wilson D., Town A., Schroeder A., Haley A., Bainbridge T., Heinrich M. C., and Corless C. L.. 2003. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 63:5761–5766.
   PubMed Web of Science ®Google Scholar
• Davies, H., Bignell G. R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M. J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B. A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G. J., Bigner D. D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J. W., Leung S. Y., Yuen S. T., Weber B. L., Seigler H. F., Darrow T. L., Paterson H., Marais R., Marshall C. J., Wooster R., Stratton M. R., and Futreal P. A.. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949–954.
   PubMed Web of Science ®Google Scholar
• Easty, D. J., and Bennett D. C.. 2000. Protein tyrosine kinases in malignant melanoma. Melanoma Res. 10:401–411.
   PubMedGoogle Scholar
• Easty, D. J., Ganz S. E., Farr C. J., Lai C., Herlyn M., and Bennett D. C.. 1993. Novel and known protein tyrosine kinases and their abnormal expression in human melanoma. J. Investig. Dermatol. 101:679–684.
   PubMedGoogle Scholar
• Edmunds, S. C., Cree I. A., Di Nicolantonio F., Hungerford J. L., Hurren J. S., and Kelsell D. P.. 2003. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br. J. Cancer 88:1403–1405.
   PubMed Web of Science ®Google Scholar
• Eisen, T., Easty D. J., Bennett D. C., and Goding C. R.. 1995. The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. Oncogene 11:2157–2164.
   PubMedGoogle Scholar
• Fujii, H., and Hamada H.. 1993. A CNS-specific POU transcription factor, Brn-2, is required for establishing mammalian neural cell lineages. Neuron 11:1197–1206.
   PubMedGoogle Scholar
• Goding, C. R. 2000. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev. 14:1712–1728.
   PubMed Web of Science ®Google Scholar
• Goodall, J., Martinozzi S., Dexter T. J., Champeval D., Carreira S., Larue L., and Goding C. R.. 2004. Brn-2 expression controls melanoma proliferation and is directly regulated by β-catenin. Mol. Cell. Biol. 24:2916–2923.
   Google Scholar
• Hagino-Yamagishi, K., Saijoh Y., Ikeda M., Ichikawa M., Minamikawa-Tachino R., and Hamada H.. 1997. Predominant expression of Brn-2 in the post-mitotic neurons of the developing mouse neocortex. Brain Res. 752:261–268.
   PubMedGoogle Scholar
• Hara, Y., Rovescalli A. C., Kim Y., and Nirenberg M.. 1992. Structure and evoution of four POU domain genes expressed in mouse brain. Proc. Natl. Acad. Sci. USA 89:3280–3284.
   PubMed Web of Science ®Google Scholar
• Hsu, S. C., Galceran J., and Grosschedl R.. 1998. Modulation of transcriptional regulation by LEF-1 in response to Wnt-1 signaling and association with β-catenin. Mol. Cell. Biol. 18:4807–4818.
   PubMed Web of Science ®Google Scholar
• Li, P., He X., Gerrero M. R., Mok M., Aggarwal A., and Rosenfeld M. G.. 1993. Spacing and orientation of bipartite DNA-binding motifs as potential functional determinants for POU domain factors. Genes Dev. 7:2483–2496.
   PubMedGoogle Scholar
• Liang, F., Schaufele F., and Gardner D. G.. 2000. Functional interaction of NF-Y and SP1 is required for type-A natriuretic peptide receptor gene transcription. J. Biol. Chem. 276:1515–1522.
   Google Scholar
• Morgenstern, J. P., and Land H.. 1990. Advanced mammalian gene transfer:high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587–3596.
   PubMed Web of Science ®Google Scholar
• Nakai, S., Kawano H., Yudate T., Nishi M., Kuno J., Nagate A., Jishage K.-i., Hamada H., Fujii H., Kawamura K., Shiba K., and Noda T.. 1995. The POU domain trnscription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. Genes Dev. 9:3109–3121.
   PubMedGoogle Scholar
• Pollock, P. M., Harper U. L., Hansen K. S., Yudt L. M., Stark M., Robbins C. M., Moses T. Y., Hostetter G., Wagner U., Kakareka J., Salem G., Pohida T., Heenan P., Duray P., Kallioniemi O., Hayward N. K., Trent J. M., and Meltzer P. S.. 2003. High frequency of BRAF mutations in nevi. Nat. Genet. 33:19–20.
   PubMed Web of Science ®Google Scholar
• Rimoldi, D., Salvi S., Lienard D., Lejeune F. J., Speiser D., Zografos L., and Cerottini J. C.. 2003. Lack of BRAF mutations in uveal melanoma. Cancer Res. 63:5712–5715.
   PubMed Web of Science ®Google Scholar
• Ryan, A. K., and Rosenfeld M. G.. 1997. POU domain family values: flexibility, partnerships, and developmental codes. Genes Dev. 11:1207–1225.
   PubMedGoogle Scholar
• Schonemann, M. D., Ryan A. K., McEvilly R. J., O'Connell S. M., Arias C. A., Kalla K. A., Li P., Sawchenko P. E., and Rosenfeld M. G.. 1995. Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2. Genes Dev. 9:3122–3155.
   PubMedGoogle Scholar
• Schreiber, E., Himmelmann A., Malpiero U., Tobler A., Stahel R., and Fontana A.. 1992. Human small cell lung cancer expresses the octamer DNA-binding and nervous system-specific transcription factor N-Oct 3 (Brain-2). Cancer Res. 52:6121–6124.
   PubMedGoogle Scholar
• Schreiber, E., Merchant R. E., Wiestler O. D., and Fontana A.. 1994. Primary brain tumors differ in their expression of octamer deoxyribonucleic acid-binding transcription factors from long-term cultured glioma cell lines. Neurosurgery 34:129–135.
   PubMedGoogle Scholar
• Sturm, R. A., Bisshop F., Takahashi H., and Parsons P. G.. 1991. A melanoma octamer binding protein is responsive to differentiating agents. Cell Growth Differ. 2:519–524.
   PubMedGoogle Scholar
• Sturm, R. A., O'Sullivan B. J., Thomson J. A., Jamshida N., Pedley J., and Parsons P. G.. 1994. Expression studies of pigmentation and POU-domain genes in human melanoma cells. Pigment Cell Res. 7:235–240.
   PubMedGoogle Scholar
• Thomson, J. A., Murphy K., Baker E., Sutherland G. R., Parsons P. G., and Sturm R. A.. 1995. The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. Oncogene 11:690–700.
   Google Scholar
• Wellbrock, C., and Schartl M.. 1999. Multiple binding sites in the growth factor receptor Xmrk mediate binding to p59fyn, GRB2 and Shc. Eur. J. Biochem. 260:275–283.
   PubMedGoogle Scholar
• Wellbrock, C., Weisser C., Geissinger E., Troppmair J., and Schartl M.. 2002. Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. J. Biol. Chem. 277:6443–6454.
   PubMedGoogle Scholar
• Wittbrodt, J., Lammers R., Malitschek B., Ullrich A., and Schartl M.. 1992. The Xmrk receptor tyrosine kinase is activated in Xiphophorus malignant melanoma. EMBO J. 11:4239–4246.
   PubMedGoogle Scholar
• Wu, M., Hemesath T. J., Takemoto C. M., Horstmann M. A., Wells A. G., Price E. R., Fisher D. Z., and Fisher D. E.. 2000. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 14:301–312.
   PubMed Web of Science ®Google Scholar
• Xu, W., Gong L., Haddad M. M., Bischof O., Campisi J., Yeh E. T., and Medrano E. E.. 2000. Regulation of microphthalmia-associated transcription factor MITF protein levels by association with the ubiquitin-conjugating enzyme hUBC9. Exp. Cell Res. 255:135–143.
   PubMed Web of Science ®Google Scholar
• Yamada, K., Tanaka T., Miyamoto K., and Noguchi T.. 2000. Sp family members and nuclear factor-Y cooperatively stimulate transcription from the rat pyruvate kinase M gene distal promoter region via their direct interactions. J. Biol. Chem. 275:18129–18137.
   PubMedGoogle Scholar
• Yavuzer, U., and Goding C. R.. 1994. Melanocyte-specific gene expression: role of repression and identification of a melanocyte-specific factor, MSF. Mol. Cell. Biol. 14:3494–3503.
   PubMedGoogle Scholar
• Zheng, X. L., Matsubara S., Diao C., Hollenberg M. D., and Wong N. C.. 2001. Epidermal growth factor induction of apolipoprotein A-I is mediated by the Ras-MAP kinase cascade and Sp1. J. Biol. Chem. 276:13822–13829.
   PubMedGoogle Scholar
• Zhong, Z. D., Hammani K., Bae W. S., and DeClerck Y. A.. 2000. NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2. J. Biol. Chem. 275:18602–18610.
   PubMedGoogle Scholar